Earnings summaries and quarterly performance for Alpha Teknova.
Executive leadership at Alpha Teknova.
Board of directors at Alpha Teknova.
Research analysts who have asked questions during Alpha Teknova earnings calls.
ML
Matthew Larew
William Blair & Company
3 questions for TKNO
Also covers: AMED, ATR, DNA +10 more
CW
Chad Wiatrowski
TD Cowen
2 questions for TKNO
Also covers: BLFS, CDXS, CTKB +4 more
MH
Matthew Hewitt
Craig-Hallum Capital Group LLC
2 questions for TKNO
Also covers: ACET, APYX, BHST +21 more
MP
Matthew Parisi
KeyBanc Capital Markets Inc.
2 questions for TKNO
Also covers: AZTA, MRVI
Vidyun Bais
BTIG
2 questions for TKNO
Also covers: AKYA, BNGO, CERS +5 more
AS
Anna Snopkowski
KeyBanc Capital Markets
1 question for TKNO
Also covers: BLFS, CYRX, RGEN
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
1 question for TKNO
Also covers: ABCL, ABSI, ARWR +19 more
JJ
Jacob Johnson
Stephens Inc.
1 question for TKNO
Also covers: AZTA, CDMO, CDXS +11 more
LB
Lucas Baranowski
KeyBanc Capital Markets Inc.
1 question for TKNO
Also covers: AZTA, LAB
Mac Etoch
Stephens Inc.
1 question for TKNO
Also covers: AZTA, CYRX, RGEN +5 more
Mark Massaro
BTIG, LLC
1 question for TKNO
Also covers: ADPT, AKYA, BLLN +19 more
ML
Matt Larew
William Blair & Co.
1 question for TKNO
Also covers: AMED, MRVI, MXCT +6 more
VC
Vivian Cervantes
BTIG
1 question for TKNO
Also covers: BNGO
Recent press releases and 8-K filings for TKNO.
Teknova announces Q3 2025 financial results and 2025 outlook
TKNO
Earnings
Guidance Update
- Teknova's total revenue for Q3 2025 increased by 9% year-over-year to $10.5 million, with Lab Essentials revenue growing 16% to $8.3 million, while Clinical Solutions revenue decreased 13% to $1.7 million.
- Gross Margin significantly improved to 30.7% in Q3 2025 from 0.9% in Q3 2024. Adjusted EBITDA was a loss of ($1.6 million) in Q3 2025, an improvement from a loss of ($5.0 million) in Q3 2024. Diluted EPS for Q3 2025 was ($0.08).
- Free Cash Flow was ($2.4 million) in Q3 2025. As of September 30, 2025, the company reported $22.1 million in cash, cash equivalents, and short-term investments.
- For the full year 2025, Teknova estimates total revenue to be between $39-42 million, representing a 7% year-over-year increase at the midpoint, and targets a Free Cash Outflow of less than $12 million. The company aims to achieve Adjusted EBITDA break-even at an annualized revenue range of $50-55 million.
Nov 6, 2025, 10:00 PM
Alpha Teknova Reports Q3 2025 Financial Results and Updates 2025 Guidance
TKNO
Earnings
Guidance Update
Demand Weakening
- Alpha Teknova reported Q3 2025 revenue of $10.5 million, a 9% increase compared to Q3 2024, primarily driven by a 16% rise in Lab Essentials revenue to $8.3 million.
- The company achieved a gross margin of 30.7% in Q3 2025, contributing to a reduced net loss of $4.3 million (negative $0.08 per diluted share) compared to $7.6 million in the prior year period.
- Alpha Teknova reiterated its 2025 total revenue guidance of $39 million-$42 million, now expecting to finish slightly below the midpoint, and maintains its FY 2025 gross margin target in the low 30s.
- While 75% of its revenue from catalog products and other market segments grew in the low double digits year-to-date, the company noted continued delays in larger purchases of custom products from biopharma customers, which represent 25% of total revenue.
- Operational efficiency projects are on track for 2026, supporting the company's confidence in scaling to over $200 million in annualized revenue without significant additional capital investments and achieving Adjusted EBITDA positive at $50 million-$55 million in annualized revenue.
Nov 6, 2025, 10:00 PM
Alpha Teknova, Inc. Reports Q3 2025 Financial Results
TKNO
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Alpha Teknova, Inc. reported $10.5 million in total revenue for the third quarter of 2025, representing a 9% increase from the prior year, marking its fifth consecutive quarter of year-over-year revenue growth.
- The company's gross margin significantly improved to 30.7% in Q3 2025, compared to 0.9% in Q3 2024, while net loss was $4.3 million (or $0.08 per diluted share) and Adjusted EBITDA was negative $1.6 million.
- Teknova reaffirmed its full-year 2025 revenue guidance of $39 million to $42 million and anticipates Free Cash Outflow to be less than $12 million.
- As of September 30, 2025, the company held $22.1 million in total cash and short-term investments, with total borrowings amounting to $13.2 million.
Nov 6, 2025, 9:08 PM
Quarterly earnings call transcripts for Alpha Teknova.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more